Status:
COMPLETED
FGF-23 Suppressibility by Calcitonin
Lead Sponsor:
Rijnstate Hospital
Conditions:
Hypophosphatemia
Eligibility:
MALE
20-55 years
Phase:
NA
Brief Summary
Introduction: Based on our experience with calcitonin as an FGF-23 suppressive agent in a patient with an FGF-23 producing tumor we hypothesize that calcitonin may be a physiologically important regu...
Eligibility Criteria
Inclusion
- Healthy man, who are between 20-55 years old, and have a BMI 20-27 kg/m2.
Exclusion
- Serum creatinin \>100 mmol/L, or glomerular filtration rate \<80 ml/min.
- Abnormal serum Ca, PO4, albumin, 25-OH vitamin D, or PTH levels.
- Any medication.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00688077
Start Date
May 1 2008
Last Update
June 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rijnstate Hospital
Arnhem, Gelderland, Netherlands